<DOC>
	<DOC>NCT01710163</DOC>
	<brief_summary>The purpose of this study is to determine whether Bipolar I Disorder refractory treatment with Quetiapine monotherapy could be better potentiated with Lithium or Aripiprazole. The investigators hypothesized that Lithium or Aripiprazole would provide similar compliance and tolerability in maintenance treatment.</brief_summary>
	<brief_title>Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients</brief_title>
	<detailed_description />
	<mesh_term>Lithium Carbonate</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Central Nervous System Depressants</mesh_term>
	<mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
	<criteria>Clinical diagnosis of Bipolar Disorder, type I, in current episode (manic/hypomanic, mixed or depression) The patient or his (her) legal representative should understand the nature of the study and sign the Informed Consent Schizophrenia or schizoaffective disorder Mental retardation Unstable clinical diseases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Lithium Carbonate</keyword>
	<keyword>Lithium</keyword>
	<keyword>Central Nervous System Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Enzyme Inhibitors</keyword>
	<keyword>Molecular Mechanisms of Pharmacological Action</keyword>
	<keyword>Neurotransmitter Agents</keyword>
	<keyword>Physiological Effects of Drugs</keyword>
	<keyword>Antimanic Agents</keyword>
	<keyword>Tranquilizing Agents</keyword>
	<keyword>Central Nervous System Depressants</keyword>
	<keyword>Psychotropic Drugs</keyword>
	<keyword>Sensory System Agents</keyword>
	<keyword>Antipsychotic Agents</keyword>
	<keyword>Antidepressive Agents</keyword>
</DOC>